The Role of Analytical Science in Implementing Quality by Design - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Role of Analytical Science in Implementing Quality by Design
The authors present topics discussed and conclusions that resulted from the PDA QbD workshop.


Pharmaceutical Technology
Volume 37, Issue 3, pp. 74-77, 80

Target state

The ultimate goal of QbD has been summarized in a statement from Janet Woodcock, director of the Center for Drug Evaluation and Research (CDER) at FDA, who suggested during a ISPE and AAPS-sponsored CMC workshop on Oct. 5, 2005, that a mutual goal of industry, society, and regulators is "a maximally efficient, agile, flexible pharmaceutical manufacturing sector that reliably produces high-quality drug products without extensive regulatory oversight." To achieve this goal, it is crucial that we move from a checkbox, compliance-focused culture to one that is founded on a science- and risk-based approach to assure quality and compliance.

Acknowledgement

The authors would like to acknowledge the support of the Parental Drug Association and the assistance of Georg Roessling, senior vice-president PDA Europe; Susanne Keitel, director of European Directorate for the Quality of Medicines; and Jean Louis Robert, chair of the EMA Quality Working Party in helping organize and facilitate the workshop.

References

1. ICH, Q8 Pharmaceutical Development (R2) (August 2009).

2. ICH, Q9 Quality Risk Management (November 2005).

3. ICH, Q10 Pharmaceutical Quality System (June 2008).

4. ICH, Q11 Development and Manufacture of Drug Substances (May 2012).

5. M. Schweitzer et al., Pharm. Technol. 34 (2), 52–59 (2010).

6. FDA, Guidance for Industry, Process Validation: General Principles and Practices, Revision 1 (January 2011).

7. EMA, Note for Guidance on Process Validation (EMA/CHMP/CVMP/QWP/70278/2012-Rev1).

8. FDA, Guidance for Industry, PAT–A Framework for Innovative Pharmaceutical Development, Manufacturing and Quality Assurance (September 2004).

9. EU, Chapter 2.9.47, European Pharmacopeia (Apr. 2012).

10. PDA, Worskshop on Analytical Science and QBD, Mar. 6–7, 2012.

11. P. Nethercote et al., PharmaManufacturing 2010, http://www.pharmamanufacturing.com/articles/2010/060.html, accessed Feb. 4, 2012.

12. USP, Medicines Compendia, General Chapter <10> (July 2011).

13. USP, General Chapter <1033> Biological Assay Validation (2010).

14. E55.02 WK16888 A Risk Based Guidance for the Validation of PAT Methods – Draft

15. FDA, Guidance for Industry, Pharmaceutical Components at Risk for Melamine Contamination (Rockville, MD, August 2009).

16. FDA, Guidance for Industry, Heparin for Drug and Medical Device Use: Monitoring Crude, Heparin for Quality, Draft Guidance (Rockville, MD, February 2012).

17. 77 Federal Register 26162, pp. 26162 -26175.

18. Guideline on the use of Near Infrared Spectroscopy (NIRS) by the pharmaceutical industry and the data requirements for new submissions and variations EMEA/CHMP/CVMP/QWP/17760/2009 Rev 2.

19. ASTM E2709–Standard Practice for demonstrating ability to comply with an acceptance procedure.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here